Table 4.
Univariate and multivariate analysis of variables and HBeAg loss after antiviral therapy in HBeAg-positive patients.
| Variables | With HBeAg loss(N = 29) | Without HBeAg loss(N = 64) | Univariate analysisP | Multivariate analysisP |
| Baseline variables | ||||
| Age (years) | 36.0 ± 8.3 | 36.2 ± 9.6 | 0.930 | |
| Male | 9 (75.0) | 11 (64.7) | 0.106 | |
| ALT (/ULN) | 4.4 (0.9, 7.2) | 1.5 (1.1, 2.6) | 0.006 | 0.056 |
| AST (/ULN) | 2.0 (0.9, 3.7) | 1.2 (0.9, 1.8) | 0.082 | |
| TBIL (μmol/L) | 13.2 (11.5, 19.8) | 14.1 (11.6, 19.6) | 0.813 | |
| HBcrAg (log10 U/mL) | 7.2 (6.1, 8.2) | 7.4 (6.5, 8.0) | 0.872 | |
| HBV DNA (log10 IU/mL) | 6.5 (4.3, 7.6) | 6.9 (5.8, 7.7) | 0.127 | |
| HBsAg (log10 IU/mL) | 3.6 (3.2, 4.3) | 3.5 (3.1, 4.0) | 0.331 | |
| Anti-HBc (log10 IU/mL) | 3.7 (3.2, 3.9) | 3.4 (3.1, 3.8) | 0.270 | |
| Decline in variables | ||||
| ΔHBcrAg (log10 U/mL) | 2.3 (1.5, 3.5) | 1.3 (0.8, 2.1) | 0.001 | 0.005 |
| ΔHBV DNA (log10 IU/mL) | 5.7 (4.2, 7.2) | 6.0 (5.0, 6.9) | 0.585 | |
| ΔHBsAg (log10 IU/mL) | 0.4 (0, 1.3) | 0.1 (−0.2, 0.6) | 0.024 | 0.661 |
| ΔAnti-HBc (log10 IU/mL) | 1.1 (0.6, 1.5) | 1.0 (0.6, 1.5) | 0.766 | |
Data are presented as n (%) or mean ± SD or median (IQR). ALT: Alanine aminotransferase; Anti-HBc: Anti-hepatitis B virus core antibody; AST: Aspartate aminotransferase; HBcrAg: Hepatitis B core-related antigen; HBeAg: Hepatitis B e antigen; HBsAg: Hepatitis B surface antigen; HBV: Hepatitis B virus; IQR: Interquartile range; SD: Standard deviation; TBIL: Total bilirubin; ULN: Upper limit of normal.